News | February 06, 2025
JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Subscribe To Our Newsletter & Stay Updated
